{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:15:22Z","timestamp":1791065722918,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ejca.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T16:46:19Z","timestamp":1378140379000},"page":"3831-3838","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00937560","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antonio","family":"Gonzalez-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Tholander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stroyakovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Perez","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Freudensprung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.08.002_b0005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.08.002_b0010","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.08.002_b0015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.08.002_b0020","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III\u2013IV epithelial ovarian cancer: a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.08.002_b0025","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.08.002_b0030","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.08.002_b0035","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study","volume":"22","author":"De Placido","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.08.002_b0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.08.002_b0045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.08.002_b0050","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.08.002_b0055","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.08.002_b0060","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.08.002_b0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","article-title":"Redefining the target: chemotherapeutics as antiangiogenics","volume":"19","author":"Miller","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.08.002_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/07357900902744510","article-title":"Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice","volume":"28","author":"Jiang","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ejca.2013.08.002_b0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2013.08.002_b0080","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15s Suppl.","key":"10.1016\/j.ejca.2013.08.002_b0085","article-title":"Multicenter randomized phase III trial of 3-weekly paclitaxel\/platinum (PC3w) versus weekly paclitaxel\/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC)","volume":"27","author":"Van der Burg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2013.08.002_b0090","volume":"31","author":"Pignata","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.08.002_b0095","unstructured":"Roche data on file, 2010: Clinical Study Report \u2013 BO17707 (ICON7). A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. Report No. 1035868, November 2010."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913007570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913007570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T20:24:56Z","timestamp":1563827096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913007570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":19,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0959804913007570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.08.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}